<DOC>
	<DOC>NCT02113696</DOC>
	<brief_summary>Ingestion of capsules of omega 3 EPA and DHA, with 1.8 g of EPA and 1.2 g DHA for morbidly obese patients, will improve the inflammatory status? C-reactive protein? Weight?</brief_summary>
	<brief_title>Intake of Omega 3 in Morbidly Obese Patients</brief_title>
	<detailed_description>Intake of EPA and DHA for the management of morbid obesity in capsules - Reduction of inflammatory factors such as adipokines, glucose, C-reactive protein, cholesterol, weight, BMI. Will be 2 groups: cases and controls. The cases will intake of omega 3 capsules and placebo control.</detailed_description>
	<mesh_term>Obesity, Morbid</mesh_term>
	<criteria>Men and women aged between 1865 years, BMI &gt; 40 kg/m2 (or &gt; 35 kg/m2 with comorbidities), ambulatory, receiving an oral diet, with a diagnosis of metabolic syndrome, and who signed a Term of Free and Informed Consent. Systemic inflammatory response syndrome, coma or compromised organ, fever or infection foci, cancer with or without chemotherapy and radiotherapy, radiotherapy, inflammatory diseases of the gastrointestinal tract, transplant, trauma, surgery or hospital stay in the past 30 days use of steroids or nonsteroid antiinflammatory or immunomodulators agents or antibiotics, or those refusing to take part in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>morbid obesity</keyword>
	<keyword>BMI at or above 4O kg/m2</keyword>
	<keyword>ingestion of omega 3</keyword>
	<keyword>inflammatory cytokines</keyword>
	<keyword>biochemical factors</keyword>
	<keyword>anthropometric factors</keyword>
</DOC>